| D2 | Scaling up the community eMTCT delivery system during COVID-19 pandemic lock down in Uganda - a case of TASO Gulu, Northern Uganda | E-poster | Impact evaluation of differentiated service delivery |
| D15 | Scaling up multi-month dispensation (MMD) of antiretroviral therapy in response to COVID-19 in Zambia | E-poster | Retention in HIV services |
| D2 | Scale-up of multi-month dispensation of antiretroviral therapy among children living with HIV as a COVID-19 mitigation measure and retention strategy, Zambia, 2020 | E-poster | Impact evaluation of differentiated service delivery |
| A43 | SARS-CoV-2-seronegative subjects target CTL epitopes in the SARS-CoV-2 nucleoprotein cross-reactive to common cold coronaviruses | Oral abstract session with live Q&A | Co-infection: SARS-Co-V2 |
| B16 | SARS-CoV-2 prevalence by self-reported HIV status: six Districts in Zambia, July 2020 | E-poster | SARS-CoV-2 |
| C15 | SARS-CoV-2 lockdown associated with expansion of HIV transmission clusters among key populations | E-poster | Surveillance in key population groups |
| A43 | SARS-Cov-2 immunity in COVID-19 convalescent individuals living with HIV: bulk immune profiling and SARS-CoV-2 specific humoral and cellular immune responses | Oral abstract session with live Q&A | Co-infection: SARS-Co-V2 |
| A43 | Sars-COV-2 and HIV in Brazil: a dangerous combination | E-poster | Co-infection: SARS-Co-V2 |
| C27 | SARS CoV-2 seroprevalence among HIV-negative participants using tenofovir/emtricitabine- based PrEP in 2020 ' a sub-study of PREVENIR-ANRS and SAPRIS-Sero | On-demand oral abstract session | PrEP |
| C27 | Safety and pharmacokinetics of oral islatravir once monthly for HIV pre-exposure prophylaxis (PrEP): week 24 analysis of a phase 2a trial | Oral abstract session with live Q&A | PrEP |